FDA approves new drug reflecting cutting-edge, ’tissue-agnostic’ effort to beat cancer

Vitrakvi, a new tissue-agnostic cancer drug — or one that targets tumors caused by TRK fusion — has been approved by the FDA, reports John Bacon for USA Today.

For many patients, this is the only possible treatment for their disease. “There had been no treatment for cancers that frequently express this mutation,” the FDA announced.

Bayer, the company behind the drug has promised to make it affordable to all who need it.

This entry was posted in Health Issues. Bookmark the permalink.
  • One World Observatory

    Learn more about the One World Observatory complimentary ticket program.

  • Categories

  • From the Newsletter

  • Upcoming Events

    1. Build-a-Rig Raffle to Honor the late NYPD Officer Scott Blackshaw

      February 5 @ 8:00 am - April 12 @ 5:00 pm
    2. Brick paver fundraiser to build a fountain at the Middletown World Trade Center Memorial Garden

      February 11 @ 8:00 am - April 30 @ 5:00 pm
    3. Applications being accepted for 2021 Richard J. Guadagno Fellow at Flight 93 National Memorial

      February 24 @ 8:00 am - March 18 @ 5:00 pm
    4. Leave a message for the family of Joseph Michael Abate, Local 3

      February 25 @ 8:00 am - March 7 @ 5:00 pm
    5. Fundraising Run to support the Lt. Joseph P. DiBernardo Memorial Foundation

      March 4 - March 6